Biovaxys Technology CorpCanadian Securities Exchange:BIOVView on OTCQB
- LAST PRICE0.0800
- TODAY'S CHANGE (%)0.0100 (14.2857%)
- Bid / Lots0.0750/ 20
- Ask / Lots0.0800/ 120
- Open / Previous Close0.0700 / 0.0700
- Day Range
- 52 Week Range
- Volume249,212
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | BIOV |
|---|---|---|
| 09:32 ET | 34000 | 0.07 |
| 09:37 ET | 2000 | 0.07 |
| 11:20 ET | 19000 | 0.075 |
| 11:32 ET | 125000 | 0.075 |
| 11:39 ET | 11000 | 0.075 |
| 11:43 ET | 5000 | 0.08 |
| 12:51 ET | 24000 | 0.08 |
| 01:00 ET | 2000 | 0.075 |
| 01:02 ET | 25000 | 0.08 |
Oct 8, 2024
Press Release: BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor, from 7:00AM ET on Tuesday Oct 08, 2024 by Dow Jones
7:00AM ET on Tuesday Oct 08, 2024 by Dow JonesPress Release: BioVaxys Engages Dr. Rajkannan Rajagopalan as Vaccine Formulations Advisor, from 7:00AM ET on Tuesday Oct 08, 2024 by Dow Jones
7:00AM ET on Tuesday Oct 08, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Biovaxys Technology Corp | 18.3M | -2.7x | --- |
Quantum BioPharma Ltd | 12.6M | -0.4x | --- |
Sirona Biochem Corp | 17.0M | -6.2x | --- |
BetterLife Pharma Inc | 16.2M | -2.7x | --- |
Resverlogix Corp | 15.3M | -1.1x | --- |
BioMark Diagnostics Inc | 21.4M | -12.3x | --- |
Company Information
BioVaxys Technology Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on improving patient lives with novel immunotherapies based on the DPX immune-educating technology platform and its HapTenix neoantigen tumor cell construct platform, for treating cancers, infectious disease, antigen desensitization and other immunological fields. The Company's clinical-stage pipeline includes maveropepimut-S, which is in phase II clinical development for advanced Relapsed-Refractory Diffuse Large B Cell Lymphoma (DLBCL) and platinum resistant ovarian cancer, and BVX-0918, a personalized immunotherapeutic vaccine using its HapTenix neoantigen tumor cell construct platform for treating refractive late-stage ovarian cancer. The Company is also leveraging its expertise in tumor immunology by creating a unique library of T-lymphocytes and other datasets post-vaccination with its personalized immunotherapeutic vaccines to identify new targetable tumor antigens.
Contact Information
- Headquarters
- 146 Thirtieth Street, Suite 100TORONTO, ON, Canada M8W 3D4
- Phone
- 604-262-8835
- Fax
- 604-262-8835
Executives
- President, Chief Operating Officer
- Kenneth Kovan
- Chief Executive Officer, Director
- James Passin
- Director
- Craig Loverock
- Independent Director
- Anthony Dutton
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $18.3M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 262.1M |
Biovaxys Technology Corp does not pay a dividend. | |
Beta | 3.63 |
EPS | $-0.03 |
Book Value | $-0.02 |
P/E Ratio | -2.7x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
